484 related articles for article (PubMed ID: 26585594)
1. Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling.
Koehler BC; Jassowicz A; Scherr AL; Lorenz S; Radhakrishnan P; Kautz N; Elssner C; Weiss J; Jaeger D; Schneider M; Schulze-Bergkamen H
BMC Cancer; 2015 Nov; 15():919. PubMed ID: 26585594
[TBL] [Abstract][Full Text] [Related]
2. Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells.
Koehler BC; Scherr AL; Lorenz S; Elssner C; Kautz N; Welte S; Jaeger D; Urbanik T; Schulze-Bergkamen H
PLoS One; 2014; 9(9):e106571. PubMed ID: 25192188
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells.
Huang S; Sinicrope FA
Autophagy; 2010 Feb; 6(2):256-69. PubMed ID: 20104024
[TBL] [Abstract][Full Text] [Related]
4. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of MCL-1 by obatoclax sensitizes Sp2/0-Ag14 hybridoma cells to glutamine deprivation-induced apoptosis.
Harnett CC; Abusneina A; Clément J; Gauthier ER
Cell Biochem Funct; 2015 Jul; 33(5):334-40. PubMed ID: 26178811
[TBL] [Abstract][Full Text] [Related]
6. Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway.
Li Y; Luo P; Wang J; Dai J; Yang X; Wu H; Yang B; He Q
Toxicol Appl Pharmacol; 2014 Jan; 274(2):319-27. PubMed ID: 24321340
[TBL] [Abstract][Full Text] [Related]
7. Obatoclax, a Pan-BCL-2 Inhibitor, Downregulates Survivin to Induce Apoptosis in Human Colorectal Carcinoma Cells Via Suppressing WNT/β-catenin Signaling.
Or CR; Huang CW; Chang CC; Lai YC; Chen YJ; Chang CC
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150830
[TBL] [Abstract][Full Text] [Related]
8. Dual Akt and Bcl-2 inhibition induces cell-type specific modulation of apoptotic and autophagic signaling in castration resistant prostate cancer cell lines.
Avsar Abdik E; Abdik H; Turan D; Sahin F; Berger MR; Kaleagasioglu F
Mol Biol Rep; 2021 Dec; 48(12):7755-7765. PubMed ID: 34647221
[TBL] [Abstract][Full Text] [Related]
9. Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK.
McCoy F; Hurwitz J; McTavish N; Paul I; Barnes C; O'Hagan B; Odrzywol K; Murray J; Longley D; McKerr G; Fennell DA
Cell Death Dis; 2010 Dec; 1(12):e108. PubMed ID: 21368880
[TBL] [Abstract][Full Text] [Related]
10. OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis.
Wroblewski D; Jiang CC; Croft A; Farrelly ML; Zhang XD; Hersey P
PLoS One; 2013; 8(12):e84073. PubMed ID: 24367627
[TBL] [Abstract][Full Text] [Related]
11. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
Peter B; Cerny-Reiterer S; Hadzijusufovic E; Schuch K; Stefanzl G; Eisenwort G; Gleixner KV; Hoermann G; Mayerhofer M; Kundi M; Baumgartner S; Sperr WR; Pickl WF; Willmann M; Valent P
J Leukoc Biol; 2014 Jan; 95(1):95-104. PubMed ID: 24052572
[TBL] [Abstract][Full Text] [Related]
12. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
[TBL] [Abstract][Full Text] [Related]
13. Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells.
Or CR; Chang Y; Lin WC; Lee WC; Su HL; Cheung MW; Huang CP; Ho C; Chang CC
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28035994
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
Konopleva M; Watt J; Contractor R; Tsao T; Harris D; Estrov Z; Bornmann W; Kantarjian H; Viallet J; Samudio I; Andreeff M
Cancer Res; 2008 May; 68(9):3413-20. PubMed ID: 18451169
[TBL] [Abstract][Full Text] [Related]
15. BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis.
Samuel S; Beljanski V; Van Grevenynghe J; Richards S; Ben Yebdri F; He Z; Nichols C; Belgnaoui SM; Steel C; Goulet ML; Shamy A; Brown D; Abesada G; Haddad EK; Hiscott J
Mol Ther; 2013 Jul; 21(7):1413-23. PubMed ID: 23689597
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
[TBL] [Abstract][Full Text] [Related]
17. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
18. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
19. Comparison of in vitro antileukemic activity of obatoclax and ABT-737.
Opydo-Chanek M; Mazur L
Tumour Biol; 2016 Aug; 37(8):10839-49. PubMed ID: 26880588
[TBL] [Abstract][Full Text] [Related]
20. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y
Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
